249 related articles for article (PubMed ID: 8646824)
1. Hepatic drug clearance in patients with mild cystic fibrosis.
Kearns GL; Crom WR; Karlson KH; Mallory GB; Evans WE
Clin Pharmacol Ther; 1996 May; 59(5):529-40. PubMed ID: 8646824
[TBL] [Abstract][Full Text] [Related]
2. Enhanced hepatic drug clearance in patients with cystic fibrosis.
Kearns GL; Mallory GB; Crom WR; Evans WE
J Pediatr; 1990 Dec; 117(6):972-9. PubMed ID: 2246703
[TBL] [Abstract][Full Text] [Related]
3. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M
Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486
[TBL] [Abstract][Full Text] [Related]
4. Liver volume as a determinant of drug clearance in children and adolescents.
Murry DJ; Crom WR; Reddick WE; Bhargava R; Evans WE
Drug Metab Dispos; 1995 Oct; 23(10):1110-6. PubMed ID: 8654200
[TBL] [Abstract][Full Text] [Related]
5. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
Figg WD; Dukes GE; Lesesne HR; Carson SW; Songer SS; Pritchard JF; Hermann DJ; Powell JR; Hak LJ
Pharmacotherapy; 1995; 15(6):693-700. PubMed ID: 8602375
[TBL] [Abstract][Full Text] [Related]
6. Beta-adrenergic blockade affects initial drug distribution due to decreased cardiac output and altered blood flow distribution.
Avram MJ; Krejcie TC; Henthorn TK; Niemann CU
J Pharmacol Exp Ther; 2004 Nov; 311(2):617-24. PubMed ID: 15197245
[TBL] [Abstract][Full Text] [Related]
7. Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects.
Andersen V; Sonne J; Larsen S
Scand J Gastroenterol; 1999 Aug; 34(8):813-7. PubMed ID: 10499483
[TBL] [Abstract][Full Text] [Related]
8. Effect of fusidic acid on the hepatic cytochrome P450 enzyme system.
Reimann G; Barthel B; Rockstroh JK; Spatz D; Brockmeyer NH
Int J Clin Pharmacol Ther; 1999 Nov; 37(11):562-6. PubMed ID: 10584978
[TBL] [Abstract][Full Text] [Related]
9. The effect of zileuton on antipyrine and indocyanine green disposition.
St Peter JV; Braeckman RA; Granneman GR; Locke CS; Cavanaugh JH; Awni WM
Clin Pharmacol Ther; 1995 Mar; 57(3):299-308. PubMed ID: 7697947
[TBL] [Abstract][Full Text] [Related]
10. Antipyrine pharmacokinetics and urinary excretion in female horses.
Dyke TM; Sams RA; Hinchcliff KW
Am J Vet Res; 1998 Mar; 59(3):280-5. PubMed ID: 9522945
[TBL] [Abstract][Full Text] [Related]
11. Effect of neurotrauma on hepatic drug clearance.
Boucher BA; Kuhl DA; Fabian TC; Robertson JT
Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):487-97. PubMed ID: 1934861
[TBL] [Abstract][Full Text] [Related]
12. Plasma elimination of indocyanine green in the intact pig after bolus injection and during constant infusion: comparison of spectrophotometry and high-pressure liquid chromatography for concentration analysis.
Ott P; Keiding S; Bass L
Hepatology; 1993 Dec; 18(6):1504-15. PubMed ID: 8244277
[TBL] [Abstract][Full Text] [Related]
13. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans.
Abernethy DR; Egan JM; Dickinson TH; Carrum G
J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045
[TBL] [Abstract][Full Text] [Related]
14. Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients.
Brockmeyer NH; Gambichler T; Bader A; Kreuter A; Kurowski M; Sander P; Altmeyer P
Eur J Med Res; 2004 Feb; 9(2):51-4. PubMed ID: 15090289
[TBL] [Abstract][Full Text] [Related]
15. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.
Kearns GL
Ann Pharmacother; 1993 Jan; 27(1):74-9. PubMed ID: 8431626
[TBL] [Abstract][Full Text] [Related]
16. Modifications of blood volume alter the disposition of markers of blood volume, extracellular fluid, and total body water.
Krejcie TC; Henthorn TK; Gentry WB; Niemann CU; Enders-Klein C; Shanks CA; Avram MJ
J Pharmacol Exp Ther; 1999 Dec; 291(3):1308-16. PubMed ID: 10565856
[TBL] [Abstract][Full Text] [Related]
17. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
[TBL] [Abstract][Full Text] [Related]
18. Comparative disposition of pharmacologic markers for cytochrome P-450 mediated metabolism, glomerular filtration rate, and extracellular and total body fluid volume of Greyhound and Beagle dogs.
KuKanich B; Coetzee JF; Gehring R; Hubin M
J Vet Pharmacol Ther; 2007 Aug; 30(4):314-9. PubMed ID: 17610404
[TBL] [Abstract][Full Text] [Related]
19. Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine.
Sharer JE; Wrighton SA
Drug Metab Dispos; 1996 Apr; 24(4):487-94. PubMed ID: 8801065
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine.
Abernethy DR; Greenblatt DJ; Divoll M; Ameer B; Shader RI
J Pharmacol Exp Ther; 1983 Mar; 224(3):508-13. PubMed ID: 6827475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
